SCHEMBL5386129

SCHEMBL5386129

CCNCCCCNCCCN

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.72
CYP2C19 P33261 3/20 0.72
CA12 O43570 3/20 0.72
CA2 P00918 3/20 0.72
CA4 P22748 3/20 0.72
CA6 P23280 3/20 0.72
CA5A P35218 3/20 0.72
CA7 P43166 3/20 0.72
CA9 Q16790 3/20 0.72
CA14 Q9ULX7 3/20 0.72
CA5B Q9Y2D0 3/20 0.72
F13A1 P00488 2/20 0.72
ALOX15 P16050 2/20 0.72
THPO P40225 2/20 0.72
MEN1 O00255 2/20 0.72
CASP2 P42575 2/20 0.72
KMT2A Q03164 2/20 0.72
RECQL P46063 1/20 0.72
HSD17B10 Q99714 1/20 0.72
TSHR P16473 3/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL763885 0.97 CYP2C19 (0.74) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL9327511 0.95 CYP2C19 (0.70) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL10045210 0.95 CYP2C19 (0.70) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL14619485 0.95 CYP2C19 (0.70) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL15139536 0.94 CA12 (0.68) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL12075033 0.94 CASP2 (0.72) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL29753171 0.94 CASP2 (0.72) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL12085529 0.94 CA12 (0.68) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL10081835 0.94 CYP2C19 (0.72) CYP1A2CYP2C19CA12CA2CA4
SCHEMBL26485 0.94

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104582695-B pharmaceutical or cosmetic composition for treating alopecia 朱利亚尼股份公司 2018-01-09 CN claimed
EP-2956117-B1 COMPOSITION FOR COSMETIC USE SUITABLE TO PRODUCE A PIGMENTATION EFFECT ON HAIR GIULIANI SPA (IT) 2017-07-19 EP claimed
EP-2983656-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION FOR RESISTING SKIN AGEING THROUGH AN ANTI-INFLAMMATORY ACTION Giuliani S.p.A. (IT) 2016-02-17 EP claimed
US-20150202132-A1 PHARMACEUTICAL OR COSMETIC COMPOSITION FOR TREATING ALOPECIA GIULIANI S.P.A. (IT) 2015-07-23 US claimed
EP-2877168-A1 PHARMACEUTICAL OR COSMETIC COMPOSITION FOR TREATING ALOPECIA Giuliani S.p.A. (IT) 2015-06-03 EP claimed
CN-104582695-A Pharmaceutical or cosmetic composition for treating alopecia GIULIANI SPA 2015-04-29 CN claimed
WO-2014167508-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION FOR RESISTING SKIN AGEING THROUGH AN ANTI-INFLAMMATORY ACTION GIULIANI S.P.A. (IT) 2014-10-16 WO claimed
WO-2014016407-A1 PHARMACEUTICAL OR COSMETIC COMPOSITION FOR TREATING ALOPECIA GIULIANI S.P.A. (IT) 2014-01-30 WO claimed
CN-101300004-A Methods of treating viral infections using polyamine analogs PATHOLOGICA LLC (US) 2008-11-05 CN claimed
WO-2023111076-A1 COSMETIC COMPOSITION FOR RESTRUCTURING HAIR AND IMPROVING THE APPEARANCE THEREOF GIULIANI S.P.A. (IT) 2023-06-22 WO disclosed
US-20220008418-A1 Aminoquinoline Derivatives and Uses Thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-01-13 US disclosed
EP-2822936-B1 AMINOQUINOLINE DERIVATIVES AND USES THEREOF MCLEAN HOSPITAL CORP (US) 2021-09-08 EP disclosed
US-11026943-B2 Aminoquinoline derivatives and uses thereof THE MCLEAN HOSPITAL CORPORATION (US) 2021-06-08 US disclosed
CN-104582695-B pharmaceutical or cosmetic composition for treating alopecia 朱利亚尼股份公司 2018-01-09 CN disclosed
US-20020045780-A1 Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment BERGERON RAYMOND J (US) 2002-04-18 US disclosed
EP-1173223-A2 CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES Slil Biomedical Corporation (US) 2002-01-23 EP disclosed
US-6235794-B1 ANTICANCER AGENT UNIVERSITY OF FLORIDA 2001-05-22 US disclosed
WO-2000066175-A2 CONJUGATES AS THERAPIES FOR CANCER AND PROSTATE DISEASES SLIL BIOMEDICAL CORPORATION (US) 2000-11-09 WO disclosed
US-4500452-A NOT SUBJECT TO ENZYME DEACTIVATION NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1985-02-19 US disclosed
US-4472304-A CARCINOSTATIC NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1984-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220008418-A1 Aminoquinoline Derivatives and Uses Thereof LRRK2, NLN, AADAT CYP1A2 2110/4885CYP2C19 2780/4885CA12 4878/4885
US-20020045780-A1 Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment SRM, SLC7A1, CATSPER1 CYP1A2 3146/4885CYP2C19 1807/4885CA12 3973/4885
US-20150202132-A1 PHARMACEUTICAL OR COSMETIC COMPOSITION FOR TREATING ALOPECIA SRM, SMS, SMOX CYP1A2 496/4885CYP2C19 1427/4885CA12 2480/4885
US-11026943-B2 Aminoquinoline derivatives and uses thereof LRRK2, NLRP3, AADAT CYP1A2 1619/4885CYP2C19 1998/4885CA12 4880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.